Vise Technologies Inc. purchased a new position in shares of Danaher Corporation (NYSE:DHR – Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 10,071 shares of the conglomerate’s stock, valued at approximately $1,989,000.
Several other hedge funds and other institutional investors have also recently modified their holdings of DHR. Red Tortoise LLC raised its holdings in Danaher by 175.0% in the second quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock worth $30,000 after purchasing an additional 98 shares in the last quarter. Ramirez Asset Management Inc. bought a new stake in shares of Danaher in the second quarter worth approximately $40,000. Costello Asset Management INC purchased a new position in shares of Danaher during the first quarter valued at approximately $41,000. Mowery & Schoenfeld Wealth Management LLC lifted its position in Danaher by 53.8% during the first quarter. Mowery & Schoenfeld Wealth Management LLC now owns 203 shares of the conglomerate’s stock valued at $42,000 after purchasing an additional 71 shares during the period. Finally, Strengthening Families & Communities LLC boosted its holdings in Danaher by 81.4% in the first quarter. Strengthening Families & Communities LLC now owns 254 shares of the conglomerate’s stock worth $52,000 after purchasing an additional 114 shares during the last quarter. 79.05% of the stock is owned by institutional investors.
Insiders Place Their Bets
In related news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 11.20% of the company’s stock.
Analysts Set New Price Targets
Read Our Latest Stock Analysis on Danaher
Danaher Stock Up 2.2%
Shares of DHR stock opened at $215.80 on Wednesday. The company’s fifty day simple moving average is $204.36 and its two-hundred day simple moving average is $200.64. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $258.23. The stock has a market cap of $152.43 billion, a P/E ratio of 44.49, a PEG ratio of 3.28 and a beta of 0.81. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33.
Danaher (NYSE:DHR – Get Free Report) last issued its quarterly earnings data on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The business had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $6 billion. During the same period in the prior year, the firm earned $1.71 EPS. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.
Danaher Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were given a dividend of $0.32 per share. The ex-dividend date of this dividend was Friday, September 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher’s payout ratio is currently 26.39%.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Articles
- Five stocks we like better than Danaher
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- 3 Beaten-Down Stocks With Rebound Potential This Earnings Season
- Industrial Products Stocks Investing
- Amazon Is One of the Clearest Buys If the Market Dips Again
- How to Buy Cheap Stocks Step by Step
- CoreWeave’s Guidance Cut: A Buying Opportunity in Disguise?
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
